Jeito Capital becomes a significant investor in HI-Bio, a clinical-stage biotech company developing targeted therapies for patients with severe immune-mediated diseases

Jeito Capital becomes a significant investor in HI-Bio, a clinical-stage biotech company developing targeted therapies for patients with severe immune-mediated diseases Jeito Capital participates in $120 million financing alongside ARCH Venture Partners and Monograph Capital HI-Bio…